3rd Circ. Pay-For-Delay Ruling Opens Door To High Court
The Third Circuit ruled Monday that payments from pharmaceutical makers to generics companies to settle patent litigation are evidence that a deal might violate federal antitrust law, rejecting the more lenient...To view the full article, register now.
Already a subscriber? Click here to view full article